Sokolski Mateusz, Reszka Konrad, Suchocki Tomasz, Adamik Barbara, Doroszko Adrian, Drobnik Jarosław, Gorka-Dynysiewicz Joanna, Jedrzejczyk Maria, Kaliszewski Krzysztof, Kilis-Pstrusinska Katarzyna, Konopska Bogusława, Kopec Agnieszka, Larysz Anna, Lis Weronika, Matera-Witkiewicz Agnieszka, Pawlik-Sobecka Lilla, Rosiek-Biegus Marta, Sokolska Justyna M, Sokolowski Janusz, Zapolska-Tomasiewicz Anna, Protasiewicz Marcin, Madziarska Katarzyna, Jankowska Ewa A
Institute of Heart Diseases, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.
Institute of Heart Diseases, University Hospital, 50-556 Wroclaw, Poland.
J Clin Med. 2022 Jan 3;11(1):241. doi: 10.3390/jcm11010241.
Patients with heart failure (HF) are at high risk of unfavorable courses of COVID-19. The aim of this study was to evaluate characteristics and outcomes of COVID-19 patients with HF.
Data of patients hospitalized in a tertiary hospital in Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 were analyzed. The study population was divided into a HF group (patients with a history of HF) and a non-HF group.
Out of 2184 patients (65 ± 13 years old, 50% male), 12% had a history of HF. Patients from the HF group were older, more often males, had more comorbidities, more often dyspnea, pulmonary and peripheral congestion, inflammation, and end-organ damage biomarkers. HF patients had longer and more complicated hospital stay, with more frequent acute HF development as compared with non-HF. They had significantly higher mortality assessed in hospital (35% vs. 12%) at three (53% vs. 22%) and six months (72% vs. 47%). Of 76 (4%) patients who developed acute HF, 71% died during hospitalization, 79% at three, and 87% at six months.
The history of HF identifies patients with COVID-19 who are at high risk of in-hospital complications and mortality up to six months of follow-up.
心力衰竭（HF）患者感染新型冠状病毒肺炎（COVID-19）后病情恶化风险较高。本研究旨在评估合并HF的COVID-19患者的特征及预后。
分析了2020年3月至2021年5月在波兰一家三级医院住院的实验室确诊COVID-19患者的数据。研究人群分为HF组（有HF病史的患者）和非HF组。
在2184例患者（65±13岁，50%为男性）中，12%有HF病史。HF组患者年龄更大，男性更多，合并症更多，更常出现呼吸困难、肺部和外周充血、炎症以及终末器官损伤生物标志物。与非HF患者相比，HF患者住院时间更长且更复杂，急性HF发生更频繁。他们在住院时（35%对12%）、3个月时（53%对22%）和6个月时（72%对47%）的死亡率显著更高。在76例（4%）发生急性HF的患者中，71%在住院期间死亡，79%在3个月时死亡，87%在6个月时死亡。
HF病史可识别出COVID-19患者，这些患者在住院并发症及长达6个月随访期内的死亡风险较高。
